Condition
Heart Failure
Locations
United Kingdom
Start date
23/10/2025
Identifiers
Trial ID NN6537-7866,
NCT number NCT07218627,
Eudract number Not Available
NCT number NCT07218627,
Eudract number Not Available
Summary
The study is testing a new drug (NNC0537-1482) to potentially treat people with heart failure. The purpose of the study is to see if NNC0537-1482 is safe and how it works in the body. Participants will either get NNC0537-1482 or placebo (a "dummy drug" without any active ingredients) and which treatment they get is decided by chance. This study will last up to 64 days with an additional screening period up to 28 days.
Trial Overview:
Treatment
DRUG: NNC0537-1482
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
Oct 23 2025 - Jan 15 2027
Participants
36
Phase
I
Are you eligible?
Gender
Male and female
Age
40 to 75 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.